Table 2. Characteristics of Covid-19 patients and matched controls.
| Covid-19 patients (%) | Control (%) | (Control -Covid) Difference (95%CI) | PVALUE | |
|---|---|---|---|---|
| Drug exposure | ||||
| ACE Inhibitor | 97,843(26.2) | 517,078(27.7) | 1.5(1.4,1.7) | 0.000 |
| ARB | 83,290(22.3) | 421,264(22.6) | 0.3(0.2,0.4) | 0.000 |
| Statin | 187,374(50.1) | 915,226(49.0) | -1.1(-1.2,-0.9) | 0.000 |
| Warfarin | 11,755(3.1) | 47,251(2.5) | -0.6(-0.7,-0.6) | 0.000 |
| Direct Factor Xa Inhibitor | 42,599(11.4) | 161,365(8.6) | -2.7(-2.9,-2.6) | 0.000 |
| P2Y12 Inhibitor | 40,199(10.7) | 157,173(8.4) | -2.3(-2.4,-2.2) | 0.000 |
| Hydroxychloroquine | 2,879(0.8) | 11,846(0.6) | -0.1(-0.2,-0.1) | 0.000 |
| Famotidine | 13,133(3.5) | 40,984(2.2) | -1.3(-1.4,-1.3) | 0.000 |
| Any drug | 278,912(74.6) | 1,351,244(72.4) | -2.2(-2.3,-2.0) | 0.000 |
| No Rx | 95,094(25.4) | 515,332(27.6) | 2.2(2.0,2.3) | 0.000 |
| Age | ||||
| 65–69 | 37,859(10.1) | 189,150(10.1) | 0.0(-0.1,0.1) | 0.839 |
| 70–74 | 89,538(23.9) | 447,650(24.0) | 0.0(-0.1,0.2) | 0.582 |
| 75–79 | 77,520(20.7) | 387,477(20.8) | 0.0(-0.1,0.2) | 0.662 |
| 80–84 | 64,951(17.4) | 324,637(17.4) | 0.0(-0.1,0.2) | 0.704 |
| 85 + | 104,138(27.8) | 517,662(27.7) | -0.1(-0.3,0.0) | 0.168 |
| Region | ||||
| MIDWEST | 90,840(24.3) | 453,053(24.3) | -0.0(-0.2,0.1) | 0.830 |
| NORTHEAST | 82,225(22.0) | 410,408(22.0) | 0.0(-0.1,0.1) | 0.976 |
| SOUTH | 139,505(37.3) | 696,758(37.3) | 0.0(-0.1,0.2) | 0.747 |
| WEST | 60,761(16.2) | 303,161(16.2) | -0.0(-0.1,0.1) | 0.946 |
| OTHER | 675(0.2) | 3,196(0.2) | -0.0(-0.0,0.0) | 0.213 |
| Unmatched | 293 (< 0.1) | - | ||
| Total | 374,299 (100) | 1,866,576 (100) | ||
| Number of patients with < 5 matches | 1446 (0.4) |